1.1A nitrile at R1
The scaffold bonds directly to the carbon of the nitrile. The linear carbon–nitrogen triple bond gives the substituent a narrow profile and places a hydrogen bond acceptor at its tip.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The scaffold bonds directly to the carbon of the nitrile. The linear carbon–nitrogen triple bond gives the substituent a narrow profile and places a hydrogen bond acceptor at its tip.
A carbon–fluorine bond occupies one attachment site, and a carbon–carbon bond attaches methyl at the other. The fluorine contributes a local bond dipole, while the methyl group adds hydrophobic surface at the neighboring position.
Each end of the linker bonds directly to one of the two sp-hybridized carbons. The geometry at those carbons aligns the attachment bonds along the triple-bond axis.
The linker attaches to the central carbon of the tert-butyl group. Three methyl branches provide a compact hydrophobic surface with tetrahedral geometry at the attachment carbon.
The oxygen connects the two neighboring carbons through single bonds. The resulting C–O–C segment has a bent geometry and provides a hydrogen bond acceptor.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A reference solution of the small molecule serves as a calibration material for testing residues on pharmaceutical equipment. A technician wipes a defined area with a solvent-wetted swab and extracts the swab into a measured volume of solvent. Liquid chromatography measures the compound in the extract, and the result is corrected using recovery measured on a reference surface of the same material.
Hydroxypropyl beta cyclodextrin replaces a portion of the organic cosolvent in an aqueous analytical preparation of the small molecule. A concentrated solution of the compound is mixed into buffered cyclodextrin solution and brought to the final volume with buffer. The cyclodextrin cavity associates reversibly with hydrophobic portions of the molecule, and liquid chromatography measures the concentration recovered in the clarified liquid.
Sealed glass inserts each hold 100 microliters of a 10 micromolar solution of the small molecule in the selected formulation vehicle. Replicate inserts are held at 4 and 25 degrees Celsius and sampled at 0, 24, and 72 hours. Liquid chromatography measures the parent compound at each time point against a freshly prepared calibration series.
A flow-through dissolution cell holds a solid dosage unit containing the small molecule, and a pump delivers temperature-controlled medium through the cell. A downstream filter retains suspended particles, and a fraction collector gathers the effluent at timed intervals. Liquid chromatography measures the dissolved concentration in each fraction, and the measured fraction volumes determine the cumulative mass released.
A humidity chamber exposes separate portions of the powdered small molecule to programmed humidity cycles at a fixed temperature. At the end of each humidity hold, replicate portions are transferred to sealed holders for powder X-ray diffraction and to vials for water-content measurement by coulometric titration. Comparison with the starting material tracks changes in crystalline form and water uptake across the cycle.
An autosampler stores sealed reference solutions and injects them at scheduled intervals alongside freshly prepared calibration solutions. Software identifies the parent peak using a retention-time window and calculates concentration from the calibration curve. The software associates each result with its vial identifier and elapsed storage time and flags values below a configured concentration threshold.
L is a methylene–oxygen–methylene segment with one terminal methylene at each attachment point. The central ether oxygen accepts hydrogen bonds, and rotation about the carbon–oxygen bonds lets the segment adopt multiple conformations.
R4 is a phenyl ring that attaches to L at ring carbon 1 and bears fluorine at ring carbon 3. The ring provides a planar aromatic surface with the carbon–fluorine bond oriented meta to the attachment site.
X1 is nitrogen with one single bond and one double bond to its neighboring scaffold atoms. In the neutral form, the nitrogen lone pair provides a hydrogen bond acceptor.
Rc is an unsubstituted cyclopropyl group attached to the X2 nitrogen through a ring carbon. The three-membered ring constrains the geometry of the two carbon–carbon bonds at that attachment carbon.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
R1 is selected from a group consisting of —C1-9alkyl, —C2-9alkenyl, —C2-9alkynyl, —NR9R10, —C1-9alkylR11, —C2-9alkenylR11, —C2-9alkynylR11, -carbocyclyl-R11, —CH(OH)C1-9alkylR9, —CH(OH)C2-9alkenylR9, —CH(OH)C2-9alkynylR9, —CH(OH)carbocyclyl-R9, —C(═O)R9, —C(═O)C1-9alkylR9, —C(═O)C2-9alkenylR9, —C(═O)C2-9alkynylR9, —C(═O)C2-9carbocyclyl-R9, —C(═O)NR9R10, —N(R9)C(═O)R9, —N(R9)C(═O)NR9R10, —N(R9)C(═O)OR9, —N(R9)C(═O)C(═NR10)R9, —N(R9)C(═O)C(═CR9R10)R9, —N(R9)C(═O)C1-4alkylN(R9)CA · US 8,680,136 B2 · ¶ 13
each R7 is independently selected from a group consisting of H, halo, —C1-9alkyl, —C2-9alkenyl, —C2-9alkynyl, —NR9R10, —OR9, —C1-9alkylCO2R9, —C2-9alkenylCO2R9, —C2-9alkynylCO2R9, and -carbocyclyl-CO2R9, or independently: (i) R6 and an R7 are taken together with the atoms to which they are attached to form a substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, (ii) R7 and an R8 are taken together with the atoms to which they are attached to fA · US 8,680,136 B2 · ¶ 18
R8 and R9 are independently selected from —H, —C1-6 alkyl, —C1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, —C1-6 alkyl-Q2, and —COOR3, alternatively R8 and R9 are taken together with the adjacent N to form a cycle selected from: V is selected from —CR24R25—, —SO2—, —O— and —NR12—;B · US 2019/0307776 A1 · claim 28
A compound having the structure of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is a 1-4 atom alkylene, optionally substituted by one or more substituents selected from the group consisting of Cl, F, CN, CF3, —R9, —OR9, —C(═O)NR9R10, and —C(═O)OR9, wherein said alkylene or alkenylene linker is optionally fused to an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclylA · US 8,680,136 B2 · claim 1
R4 is selected from —H, —C1-6 alkyl, —C1-6 alkyl-C(OR3)2—C3-6 cycloalkyl, —C1-6 substituted alkyl, —C1-6 alkyl-C3-6 cycloalkyl, —C1-6 alkyl-Q1, —C1-6 alkyl-C3-6 cycloalkyl-Q1, aryl, heteroaryl, substituted heteroaryl, —COR6, —COCOR6, —SO2R7, and —SO2NR2R2, wherein Q1 is selected from C3-10 carbocycle, substituted C3-10 carbocycle, C3-10 heterocycle, substituted C3-10 heterocycle, aryl, heteroaryl, substituted heteroaryl, halogen, —CF3, —OR2, —COOR2, —NR8R9, —CONR10R11 and —SOB · US 2019/0307776 A1 · claim 28
“Azaindole” means one of the “CH” moieties in the 6-member ring of an indole is substituted with a nitrogen atom.B · US 2019/0307776 A1 · ¶ 70
Ra is C1-6 alkyl, NR2R2, Rb is —H, —C1-6 alkyl, —COR3, —SO2R3, —SONR3R3, R5 is selected from —H, —C1-6 alkyl, —C3-6 cycloalkyl, —C1-6 alkylsubstituted alkyl, —C1-6 alkyl-NR8R9, —COR6, —COCOR6, —SO2R7 and —SO2NR2R2; with the proviso that only one of R4 or R5 can be selected from —COR6, —COCOR6, —SO2R7 and —SO2NR2R2;B · US 2019/0307776 A1 · claim 28
R12 is selected from a group consisting of H, C1-9alkyl, —(CH2)0-3—R11, —C(R13)2OC(O)C1-9alkyl, —C(R13)2OC(O)R11, —C(R13)2OC.(O)OC1-9alkyl and —C(R13)2OC(O)OR11; each R13 is independently selected from a group consisting of H and C1-4-alkyl; and m is independently an integer from 1 to 2, wherein each C1-9alkyl, C2-9alkenyl, and C2-9alkynyl is independently optionally substituted.A · US 8,680,136 B2 · claim 1
R24 and R25 are independently from the group of H, —C1-6 alkyl, —C1-6 substituted alkyl, —C1-6 alkyl-Q5, —C1-6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and Q5 is selected from halogen and SO2R3, R26 and R27 are independently selected from —H, —C1-6 alkyl, —C1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, —C1-6 alkyl-Q2, andB · US 2019/0307776 A1 · ¶
R10 and R11 are independently selected from —H, —C1-6 alkyl, —C1-6 substituted alkyl and —C3-6 cycloalkyl, alternatively R10 and R11 are taken together with the adjacent N to form a cycle such as R12 is selected from —C1-6 alkyl, —C1-6 alkyl-OH; —C1-6 alkyl, —C1-6 substituted alkyl,-C3-6 cycloalkyl, —COR7, —COONR22R23, —SORT, and —SONR24R25;B · US 2019/0307776 A1 · claim 28
An empty cell means only that no passage was reproduced there.
The present invention relates to antimicrobial compounds, compositions, their use and preparation as therapeutic agents.A · US 8,680,136 B2 · ¶ 2
The rapid spread of bacterial resistance and the evolution of multi-resistant strains severely limits β-lactam treatment options available.A · US 8,680,136 B2 · ¶ 4
Despite the armamentarium of agents and drug combinations, there remains a medical need for new anti-retroviral agents, due in part to the need for chronic dosing to combat infection.B · US 2019/0307776 A1 · ¶ 4
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions, and their use in inhibiting HIV and treating those infected with HIV or AIDS.B · US 2019/0307776 A1 · ¶ 7
patent.fyi, US 2026/0355184 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355184/, SHA-256 8855a309bf557d2fc9e65ea1bf418ab52ff93347bbf27385a4f789a68882cdd7